Expression and differential signaling of heregulins in pancreatic cancer cells

Armin Kolb, Jörg Kleeff, Nichole Arnold, Nathalia A. Giese, Thomas Giese, Murray Korc, Helmut Friess

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

The EGF Family of ligands and receptors plays an important role in the pathogenesis of pancreatic clinical adenocarcinoma (PDAC) and contributes to its aggressiveness. A number of molecular approaches have been developed to block these pathways, and studies have already proven the clinical benefit of this concept in PDAC. In the present study, we sought to determine the potential role of heregulins (HRGs), a family of EGF-like growth factors, in PDAC. Quantitative RT-PCR analysis revealed that HRGs as well as its signaling ErbB receptors were present in 4 of 4 human pancreatic cancer cell lines (PCCL). HKR-β1 stimulated the growth of 3 of 4 PCCL, whereas HRG-α1 inhibited cell growth in 3 of 4 cell lines. Responses towards HRGs could in part be predicted by ErbB2 and ErbB3 expression levels. HRGs induced phosphorylation of different ErbB receptors as well as activation of MAPk, p38MAPK, JNK and PI3K in a cell- and ligand-specific manner. In vivo, HRG was upregulated in pancreatic cancer tissues and localized predominantly in the cancer cells. High HRG-β levels but not HRG-α levels were associated with decreased patient survival. In conclusion, HRG is expressed by pancreatic cancer cells and influences pancreatic cancer cell growth and patient survival.

Original languageEnglish (US)
Pages (from-to)514-523
Number of pages10
JournalInternational Journal of Cancer
Volume120
Issue number3
DOIs
StatePublished - Feb 1 2007
Externally publishedYes

Fingerprint

Neuregulin-1
Pancreatic Neoplasms
Cell Line
Growth
Survival
Phosphatidylinositol 3-Kinases
Epidermal Growth Factor
Intercellular Signaling Peptides and Proteins
Adenocarcinoma
Phosphorylation
Ligands
Polymerase Chain Reaction

Keywords

  • Epidermal growth factor
  • Heregulin
  • Pancreatic cancer
  • Phosphorylation
  • Tyrosine kinase

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Kolb, A., Kleeff, J., Arnold, N., Giese, N. A., Giese, T., Korc, M., & Friess, H. (2007). Expression and differential signaling of heregulins in pancreatic cancer cells. International Journal of Cancer, 120(3), 514-523. https://doi.org/10.1002/ijc.22360

Expression and differential signaling of heregulins in pancreatic cancer cells. / Kolb, Armin; Kleeff, Jörg; Arnold, Nichole; Giese, Nathalia A.; Giese, Thomas; Korc, Murray; Friess, Helmut.

In: International Journal of Cancer, Vol. 120, No. 3, 01.02.2007, p. 514-523.

Research output: Contribution to journalArticle

Kolb, A, Kleeff, J, Arnold, N, Giese, NA, Giese, T, Korc, M & Friess, H 2007, 'Expression and differential signaling of heregulins in pancreatic cancer cells', International Journal of Cancer, vol. 120, no. 3, pp. 514-523. https://doi.org/10.1002/ijc.22360
Kolb, Armin ; Kleeff, Jörg ; Arnold, Nichole ; Giese, Nathalia A. ; Giese, Thomas ; Korc, Murray ; Friess, Helmut. / Expression and differential signaling of heregulins in pancreatic cancer cells. In: International Journal of Cancer. 2007 ; Vol. 120, No. 3. pp. 514-523.
@article{d7aed866329149e987c269ed7b0bc3a6,
title = "Expression and differential signaling of heregulins in pancreatic cancer cells",
abstract = "The EGF Family of ligands and receptors plays an important role in the pathogenesis of pancreatic clinical adenocarcinoma (PDAC) and contributes to its aggressiveness. A number of molecular approaches have been developed to block these pathways, and studies have already proven the clinical benefit of this concept in PDAC. In the present study, we sought to determine the potential role of heregulins (HRGs), a family of EGF-like growth factors, in PDAC. Quantitative RT-PCR analysis revealed that HRGs as well as its signaling ErbB receptors were present in 4 of 4 human pancreatic cancer cell lines (PCCL). HKR-β1 stimulated the growth of 3 of 4 PCCL, whereas HRG-α1 inhibited cell growth in 3 of 4 cell lines. Responses towards HRGs could in part be predicted by ErbB2 and ErbB3 expression levels. HRGs induced phosphorylation of different ErbB receptors as well as activation of MAPk, p38MAPK, JNK and PI3K in a cell- and ligand-specific manner. In vivo, HRG was upregulated in pancreatic cancer tissues and localized predominantly in the cancer cells. High HRG-β levels but not HRG-α levels were associated with decreased patient survival. In conclusion, HRG is expressed by pancreatic cancer cells and influences pancreatic cancer cell growth and patient survival.",
keywords = "Epidermal growth factor, Heregulin, Pancreatic cancer, Phosphorylation, Tyrosine kinase",
author = "Armin Kolb and J{\"o}rg Kleeff and Nichole Arnold and Giese, {Nathalia A.} and Thomas Giese and Murray Korc and Helmut Friess",
year = "2007",
month = "2",
day = "1",
doi = "10.1002/ijc.22360",
language = "English (US)",
volume = "120",
pages = "514--523",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Expression and differential signaling of heregulins in pancreatic cancer cells

AU - Kolb, Armin

AU - Kleeff, Jörg

AU - Arnold, Nichole

AU - Giese, Nathalia A.

AU - Giese, Thomas

AU - Korc, Murray

AU - Friess, Helmut

PY - 2007/2/1

Y1 - 2007/2/1

N2 - The EGF Family of ligands and receptors plays an important role in the pathogenesis of pancreatic clinical adenocarcinoma (PDAC) and contributes to its aggressiveness. A number of molecular approaches have been developed to block these pathways, and studies have already proven the clinical benefit of this concept in PDAC. In the present study, we sought to determine the potential role of heregulins (HRGs), a family of EGF-like growth factors, in PDAC. Quantitative RT-PCR analysis revealed that HRGs as well as its signaling ErbB receptors were present in 4 of 4 human pancreatic cancer cell lines (PCCL). HKR-β1 stimulated the growth of 3 of 4 PCCL, whereas HRG-α1 inhibited cell growth in 3 of 4 cell lines. Responses towards HRGs could in part be predicted by ErbB2 and ErbB3 expression levels. HRGs induced phosphorylation of different ErbB receptors as well as activation of MAPk, p38MAPK, JNK and PI3K in a cell- and ligand-specific manner. In vivo, HRG was upregulated in pancreatic cancer tissues and localized predominantly in the cancer cells. High HRG-β levels but not HRG-α levels were associated with decreased patient survival. In conclusion, HRG is expressed by pancreatic cancer cells and influences pancreatic cancer cell growth and patient survival.

AB - The EGF Family of ligands and receptors plays an important role in the pathogenesis of pancreatic clinical adenocarcinoma (PDAC) and contributes to its aggressiveness. A number of molecular approaches have been developed to block these pathways, and studies have already proven the clinical benefit of this concept in PDAC. In the present study, we sought to determine the potential role of heregulins (HRGs), a family of EGF-like growth factors, in PDAC. Quantitative RT-PCR analysis revealed that HRGs as well as its signaling ErbB receptors were present in 4 of 4 human pancreatic cancer cell lines (PCCL). HKR-β1 stimulated the growth of 3 of 4 PCCL, whereas HRG-α1 inhibited cell growth in 3 of 4 cell lines. Responses towards HRGs could in part be predicted by ErbB2 and ErbB3 expression levels. HRGs induced phosphorylation of different ErbB receptors as well as activation of MAPk, p38MAPK, JNK and PI3K in a cell- and ligand-specific manner. In vivo, HRG was upregulated in pancreatic cancer tissues and localized predominantly in the cancer cells. High HRG-β levels but not HRG-α levels were associated with decreased patient survival. In conclusion, HRG is expressed by pancreatic cancer cells and influences pancreatic cancer cell growth and patient survival.

KW - Epidermal growth factor

KW - Heregulin

KW - Pancreatic cancer

KW - Phosphorylation

KW - Tyrosine kinase

UR - http://www.scopus.com/inward/record.url?scp=33845691807&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845691807&partnerID=8YFLogxK

U2 - 10.1002/ijc.22360

DO - 10.1002/ijc.22360

M3 - Article

C2 - 17096356

AN - SCOPUS:33845691807

VL - 120

SP - 514

EP - 523

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 3

ER -